scholarly journals Endothelial Progenitor Cells Predict Long-Term Mortality in Hemodialysis Patients

2016 ◽  
Vol 13 (3) ◽  
pp. 240-247 ◽  
Author(s):  
Chien-Lin Lu ◽  
Jyh-Gang Leu ◽  
Wen-Chih Liu ◽  
Cai-Mei Zheng ◽  
Yuh-Feng Lin ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Hemodialysis Patients ◽  
Endothelial Progenitor ◽  
Long Term Mortality

Putative endothelial progenitor cells predict long-term mortality in type-2 diabetes

Endocrine ◽  
2018 ◽  
Vol 62 (1) ◽  
pp. 263-266 ◽  
Author(s):  
Colin Gerard Egan ◽  
Cecilia Fondelli ◽  
Enrico Pierantozzi ◽  
Giovanni Tripepi ◽  
Francesco Dotta ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Endothelial Progenitor ◽  
Long Term Mortality

scholarly journals Does erythropoietin therapy affect circulating endothelial cells in hemodialysis patients?

2020 ◽  
pp. 29-37
Author(s):  
T. Bulduk ◽  
A. U. Yalcin ◽  
O. M. Akay ◽  
S. G. Ozkurt ◽  
H. U. Teke ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Endothelial Progenitor Cell ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Hemodialysis Patients ◽  
Circulating Endothelial Cells ◽  
Control Group ◽  
Endothelial Progenitor

Anemia is a common complication of chronic kidney disease (CKD). The most common cause of anemia in CKD is erythropoietin deficiency; and the most important cause of mortality in CKD patients is atherosclerotic vascular complications which are associated with endothelial damage. One of the methods evaluating vascular integrity is the cytometric measurement of circulating endothelial cells and endothelial progenitor cells in peripheral blood. The study aimed to investigate the effects of erythropoietin therapy on endothelial dysfunction by evaluating circulating endothelial cells and endothelial progenitor cells in peripheral blood using the technique of flow cytometry. Methods. A total of 55 hemodialysis patients were evaluated in three groups; those having erythropoietin therapy for at least last 3 months (n = 20) / not having erythropoietin for at least the last 3 months (n = 20) and the patients who started erythropoietin treatment during the study (n = 5). The control group consisted of 20 people. Blood values of the 3rd Group were investigated three times as baseline, 2nd week and 8th week CD34 +, CD105 + cells were evaluated as activated circulating endothelial cells; CD133 +, CD146 + cells were evaluated as activated endothelial progenitor cells. Results. There was no difference between the patients and healthy individuals in terms of circulating endothelial cells and endothelial progenitor cells. In the third group, no differences were observed in circulating endothelial cells / endothelial progenitor cell levels at baseline / 2nd and 8th weeks. There was no correlation between erythropoietin and circulating endothelial cells / endothelial progenitor cells. Conclusion. A correlation is not available between the therapeutic doses of erythropoietin used in hemodialysis patients and circulating endothelial cells / endothelial progenitor cell levels; supratherapeutic doses could change the results.

Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis

2004 ◽  
Vol 44 (5) ◽  
pp. 840-849 ◽  
Author(s):  
Kay Herbrig ◽  
Frank Pistrosch ◽  
Uta Oelschlaegel ◽  
Gunnar Wichmann ◽  
Andrea Wagner ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Endothelial Progenitor ◽  
Migratory Activity
Sign in / Sign up

Export Citation Format

Share Document